TP53 and ovarian carcinoma: A Ca2+ agent, in combination with SSD, overcame chemoresistance via p53 overexpression and induced G2/M arrest, mitochondrial fission, and apoptotic cell death via Ca2+ release in ovarian cancer cells [16].